- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Casey McPherson Shares His Journey With Rare Drug Development and Chrysalis Genetics
Casey McPherson, Founder and CEO of Chrysalis Genetics, talks about his daughter's rare genetic condition, and how it led him to antisense oligonucleotides (ASOs) and therapeutic development for rare diseases.
Casey McPherson, Founder and CEO of Chrysalis Genetics, has an interesting background for someone developing genetic technologies to help treat rare diseases. As a musician based in Austin, Texas, McPherson was inspired to enter the world of drug development and biotechnology after his daughter was diagnosed with a rare genetic condition. In this Pharmaceutical Executive interview, McPherson talks about his journey toward developing a therapeutic for his daughter, as well as changing the overall landscape of therapeutic research for children with rare or ultra-rare genetic diseases.
Interview discussion points:
08:06 - Commercializing rare disease drugs for global populations
11:10 - McPherson shares his thoughts on the future of the rare disease landscape, including shifting regulatory paths
14:23 - Lessons learned to guide other entrepreneurs in the biotech industry
17:00 - Advice for parents navigating the rare/ultra-rare disease space
